GSK Investigational Site

Bedford Park, South Australia 5043

0 studies enrolling now · 20 studies all time

What they study most

Acute Coronary Syndrome, Asthma, Atherosclerosis, Bowel Dysfunction, Constipation, Influenza, Human, Irritable Colon, Neoplasms, Neoplasms, Breast, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis

Studies at this site

• Extended Access of Momelotinib in Adults With Myelofibrosis — Running, not enrolling
• A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer — Stopped early
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma — Completed
• A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects — Completed
• A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma — Completed
• A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects — Completed
• A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation — Completed
• Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain — Completed
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial — Completed
• A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) — Completed
• Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer — Completed
• Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital — Completed
• Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma — Completed
• Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain — Completed
• Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS) — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed